David J. Schneider

13.8k total citations · 2 hit papers
193 papers, 9.5k citations indexed

About

David J. Schneider is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Hematology. According to data from OpenAlex, David J. Schneider has authored 193 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Cardiology and Cardiovascular Medicine, 61 papers in Surgery and 42 papers in Hematology. Recurrent topics in David J. Schneider's work include Antiplatelet Therapy and Cardiovascular Diseases (59 papers), Acute Myocardial Infarction Research (41 papers) and Venous Thromboembolism Diagnosis and Management (31 papers). David J. Schneider is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (59 papers), Acute Myocardial Infarction Research (41 papers) and Venous Thromboembolism Diagnosis and Management (31 papers). David J. Schneider collaborates with scholars based in United States, Canada and Spain. David J. Schneider's co-authors include Burton E. Sobel, Daniel M. Wegner, Teri L. White, Friederike K. Keating, Deepak L. Bhatt, Atul Aggarwal, C. Michael Gibson, Sabina A. Murphy, Shinya Goto and Jean‐Pierre Bassand and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Personality and Social Psychology.

In The Last Decade

David J. Schneider

188 papers receiving 9.0k citations

Hit Papers

Paradoxical effects of thought suppression. 1987 2026 2000 2013 1987 2011 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Paradoxical effects of thought suppression.
    1987 1.5k citations David J. Schneider et al. profile →
  2. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
    2011 1.3k citations David J. Schneider, C. Michael Gibson et al. profile →

Peers

David J. Schneider
Jonathan Golledge Australia
Richard Charnigo United States
Eric Q. Wu United States
Maarten P. van den Berg Netherlands
Meyer Friedman United Kingdom
William C. Nichols United States
Jennifer H. Barrett United Kingdom
Lisa Blackwell United States
Michael Feldstein United States
James R. Cook United States
Jonathan Golledge Australia
David J. Schneider
Citations per year, relative to David J. Schneider David J. Schneider (= 1×) peers Jonathan Golledge

Countries citing papers authored by David J. Schneider

Since Specialization
Citations

This map shows the geographic impact of David J. Schneider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Schneider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Schneider more than expected).

Fields of papers citing papers by David J. Schneider

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Schneider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Schneider. The network helps show where David J. Schneider may publish in the future.

Co-authorship network of co-authors of David J. Schneider

This figure shows the co-authorship network connecting the top 25 collaborators of David J. Schneider. A scholar is included among the top collaborators of David J. Schneider based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Schneider. David J. Schneider is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harrison, Stephen A., Vlad Ratziu, Quentin M. Anstee, et al.. (2023). Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 59(1). 51–63. 56 indexed citations
2.
Schneider, David J., T Honda, Edward Feldmann, et al.. (2022). Platelet FcγRIIa Expression in Ischemic Stroke: A Marker of Increased Platelet Reactivity. SHILAP Revista de lepidopterología. 2(3). e000201–e000201. 2 indexed citations
3.
4.
Schneider, David J., et al.. (2021). Influence of Lipid Excipients on Platelet Function and the Pharmacodynamic Effects of Aspirin. Journal of Cardiovascular Pharmacology. 78(2). 297–301. 3 indexed citations
5.
Angiolillo, Dominick J., Jerrold H. Levy, Lisa K. Jennings, & David J. Schneider. (2020). The Role of Platelet Function Testing in Improving Clinical Outcomes. 1 indexed citations
6.
Genuth, Saul, Helen Vlachos, Maria M. Brooks, et al.. (2019). BARI 2D: A Reanalysis Focusing on Cardiovascular Events. Mayo Clinic Proceedings. 94(11). 2249–2262. 1 indexed citations
7.
Toennes, Stefan W., David J. Schneider, Werner Pogoda, et al.. (2019). Excretion of 4-fluoroamphetamine and three metabolites in urine after controlled oral ingestion. Journal of Pharmaceutical and Biomedical Analysis. 179. 113008–113008. 5 indexed citations
8.
Schneider, David J., et al.. (2016). Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery. Coronary Artery Disease. 27(3). 185–190. 4 indexed citations
9.
Lakings, Duane B., M.C. Janzen, & David J. Schneider. (2012). Pharmacokinetic modeling of the high-dose bolus regimen of tirofiban in patients with severe renal impairment. Coronary Artery Disease. 23(3). 208–214. 3 indexed citations
10.
Schneider, David J.. (2011). Current Issues with Glycoprotein IIb-IIIa Antagonists. Current Drug Targets. 12(12). 1813–1820. 2 indexed citations
11.
Chaitman, Bernard, Regina M. Hardison, Dale Adler, et al.. (2009). The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease. Circulation. 120(25). 2529–2540. 169 indexed citations
12.
Keating, Friederike K., Mark Fung, & David J. Schneider. (2008). Induction of platelet white blood cell (WBC) aggregate formation by platelets and WBCs in red blood cell units. Transfusion. 48(6). 1099–1105. 6 indexed citations
13.
Sternberg, Robert J., Diane F. Halpern, Henry L. Roediger, et al.. (2006). Critical Thinking in Psychology. Cambridge University Press eBooks. 39 indexed citations
14.
Gogo, Prospero, David J. Schneider, Matthew W. Watkins, et al.. (2005). Systemic Inflammation After Drug-Eluting Stent Placement. Journal of Thrombosis and Thrombolysis. 19(2). 87–92. 33 indexed citations
15.
Schneider, David J., et al.. (2004). Efficiency in clinical research: assessment in vitro of potential anti-thrombotic drug interactions. Coronary Artery Disease. 15(3). 177–181. 4 indexed citations
16.
Butenas, Saulius, Marcus E. Carr, Farouc A. Jaffer, et al.. (2003). Bivalirudin, thrombin and platelets: clinical implications and future directions.. PubMed. Suppl. 2–15. 3 indexed citations
17.
Keating, Friederike K., Burton E. Sobel, & David J. Schneider. (2003). Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. The American Journal of Cardiology. 92(11). 1362–1365. 114 indexed citations
18.
19.
20.
Schneider, David J., Paula B. Tracy, & Burton E. Sobel. (1998). Acute Coronary Syndromes: 2. Antiplatelet Agents. Hospital Practice. 33(5). 107–130. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan Golledge Breakdown of academic impact, for papers by Richard Charnigo Breakdown of academic impact, for papers by Eric Q. Wu Breakdown of academic impact, for papers by Maarten P. van den Berg Breakdown of academic impact, for papers by Meyer Friedman Breakdown of academic impact, for papers by William C. Nichols Breakdown of academic impact, for papers by Jennifer H. Barrett Breakdown of academic impact, for papers by Lisa Blackwell Breakdown of academic impact, for papers by Michael Feldstein Breakdown of academic impact, for papers by James R. Cook
Rankless by CCL
2026